Agfa waits on antitrust approval for Mitra deal
This article was originally published in Clinica
Agfa-Gevaert will know by early January 2002 whether it will be able to acquire its long-time technology partner, Mitra. That is the date by which the Mortsel, Belgium-based company expects to have heard whether its offer has gone through the premerger clearance process. The companies have operated together for the last 10 years, with observers claiming that Mitra has played an integral role in developing Agfa's Impax PACS system over that period (see Clinica No 977, p 13).
You may also be interested in...
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.